A Phase 1/2 interventional study of Bomedemstat in Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) and Post-essential Thrombocythemia Myelofibrosis (PET-MF), sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 453 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.
Among the 453 studies in Primary Myelofibrosis with a site in United States, this one is the 91st largest by enrollment of the 387 interventional ones that give a count, is one of 15 that started in 2017, is one of 49 in phase 1/2, and was the 307th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →70 of the 453 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Damora Therapeutics · Sites in United States, Australia
Ages 18+
University of Utah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
453 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 166 · Phase 2 219 · Phase 3 45
First in 1992; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 43 across 490 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 40 across the 387 interventional studies, 153 across the 35 observational. Of the 328 that completed or were terminated, 152 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 453 have an industry lead sponsor. The 10 most frequent:
This study is registered under Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Merck & Co., Inc has 4 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
40 of the studies in Primary Myelofibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT02934477Center for International Blood and Marrow Transplant ResearchProspective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | 2026-11 |
| NCT01973881University of Michigan Rogel Cancer CenterQuantitative MRI for Myelofibrosis | 2026-12 |
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 453 studies in Primary Myelofibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543), administered orally once daily in participants with myelofibrosis.
The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera-myelofibrosis (PPVMF), and post-essential thrombocythaemia-myelofibrosis (PET-MF) (collectively referred to as 'MF'); inhibition of LSD1 by bomedemstat will reduce spleen size in those with splenomegaly, improve haematopoiesis and reduce constitutional symptoms associated with these disorders.
This study initiated as a Phase 1/2a study assessing the safety of the starting dose, an 85-day duration of treatment, and the PK and PD effects of bomedemstat, with transition to a Phase 2b study incorporating changes supported by the Phase 1/2a data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP). Qualifying participants could continue to receive treatment for an additional 85 days during an Additional Treatment Period (ATP) as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
Drug: Bomedemstat
Oral (capsule) administration according to dose allocation.
Also known as: IMG-7289, MK-3543, LSD1 inhibitor
Number of Participants With Dose Limiting Toxicities (DLTs)
DLT was defined as any one of the following adverse events (AEs) that occured through Day 7 of the Initial Treatment Period (ITP) and was considered by the Investigator to be possibly, probably or definitely related to bomedemstat: * Thrombocytopenia leading to clinically significant sequelae (i.e., a clinically significant bleeding event or the need for prophylactic transfusions) * A clinically significant bleeding event in a participant with a platelet count \>50 x 10\^9/L (50 k/μL) * Any Grade 4 or 5 non-haematologic adverse event * Any Grade 3 non-haematologic adverse event with failure to recover to Grade 2 within 7 days of drug cessation, with the following exceptions: ≥ Grade 3 nausea, vomiting or diarrhea that responds to standard medical care; ≥ Grade 3 aesthenia lasting less than 14 days; any Grade 3 electrolyte abnormality unrelated to the underlying malignancy and persisting greater than 24 hours. The number of participants with a DLT were reported.
Time frame: Up to Day 7 of the ITP
Number of Participants With Serious Adverse Events
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. Serious AEs (SAEs) were any AE that resulted in death, life-threatening experience, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly, or important medical events. The number of participants with at least one treatment-emergent (TE) SAE was reported for each arm.
Time frame: Up to approximately 30 months
Number of Participants With Adverse Events
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. The number of participants with at least one TE AE was reported for each arm.
Time frame: Up to approximately 30 months
Number of Participants That Discontinued Study Treatment Due To AEs
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. The number of participants that discontinued study treatment with bomedemstat due to a TE AE was reported for each arm.
Time frame: Up to approximately 29 months
Phase 1/2a Portion: Observed Maximum Concentration (Cmax) of Bomedemstat
Cmax was defined as the maximum observed concentration after administration obtained directly from the concentration time profile. Blood and plasma samples were collected at pre-specified timepoints to calculate Cmax in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
Time frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
Phase 1/2a Portion: Time to Maximum Concentration (Tmax) of Bomedemstat
Tmax was defined as the time to maximum concentration after administration obtained by inspection. Blood and plasma samples were collected at pre-specified timepoints to calculate Tmax in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
Time frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
Phase 1/2a Portion: Area Under the Concentration-time Curve of Bomedemstat From Time 0 to 24 Hours Post-dose (AUC0-24)
AUC0-24 was defined as the area under the concentration versus time curve calculated using the linear trapezoidal rule from the zero time-point to the 24-hour time-point concentration. Blood and plasma samples were collected at pre-specified timepoints to calculate AUC0-24 in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
Time frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
Phase 1/2a Portion: Apparent Total Clearance (CL/F) of Bomedemstat After Oral Administration
CL/F was defined as the apparent total clearance of drug after oral administration. Blood and plasma samples were collected at pre-specified timepoints to calculate CL/F in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
Time frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
Percentage Change From Baseline in Spleen Volume
Change in spleen volume was assessed based on calculated spleen volume (ml) measured by magnetic resonance imaging (MRI), or computerized tomography (CT) scan (where locally permitted) if the participant was not a candidate for MRI from Day 0. Percentage change from baseline in spleen volume was reported at Initial Treatment Period (ITP) Day 84, ITP Day 168, Additional Treatment Period 1 (ATP1) Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337).
Time frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337)
Percentage Change From Baseline in Spleen Size
Change in spleen size was assessed based on spleen palpation (in cm) at each visit. Percentage change from baseline in spleen size was reported at ITP Day 84, ITP Day 168, ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591). As prespecified by the Statistical Analysis Plan, assessments for the Phase 1/2 groups were summarized using visit windowing after the Day 84 visit of the ITP to allow for comparison with the Phase 2b groups at ITP Day 168.
Time frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591)
Participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF) were recruited for this study.
| Milestone | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| Started | 9 | 3 | 6 | 8 | 5 | 11 | 24 | 11 | 13 |
| Treated | 9 | 3 | 6 | 8 | 5 | 11 | 24 | 11 | 13 |
| Entered additional treatment period (atp) | 6 | 2 | 3 | 3 | 1 | 4 | 17 | 5 | 9 |
| Completed initial treatment period (itp) | 7 | 3 | 4 | 4 | 1 | 4 | 18 | 8 | 10 |
| Completed | 1 | 0 | 0 | 2 | 0 | 3 | 14 | 5 | 7 |
| Not completed | 8 | 3 | 6 | 6 | 5 | 8 | 10 | 6 | 6 |
| Withdrew: Adverse event | 0 | 1 | 3 | 1 | 2 | 2 | 5 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 3 | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 1 |
| Withdrew: Protocol defined disease progression | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Withdrew: Not reported | 4 | 1 | 0 | 1 | 0 | 2 | 1 | 1 | 0 |
DLT was defined as any one of the following adverse events (AEs) that occured through Day 7 of the Initial Treatment Period (ITP) and was considered by the Investigator to be possibly, probably or definitely related to bomedemstat: * Thrombocytopenia leading to clinically significant sequelae (i.e., a clinically significant bleeding event or the need for prophylactic transfusions) * A clinically significant bleeding event in a participant with a platelet count \>50 x 10\^9/L (50 k/μL) * Any Grade 4 or 5 non-haematologic adverse event * Any Grade 3 non-haematologic adverse event with failure to recover to Grade 2 within 7 days of drug cessation, with the following exceptions: ≥ Grade 3 nausea, vomiting or diarrhea that responds to standard medical care; ≥ Grade 3 aesthenia lasting less than 14 days; any Grade 3 electrolyte abnormality unrelated to the underlying malignancy and persisting greater than 24 hours. The number of participants with a DLT were reported.
| Participants | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. Serious AEs (SAEs) were any AE that resulted in death, life-threatening experience, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly, or important medical events. The number of participants with at least one treatment-emergent (TE) SAE was reported for each arm.
| Participants | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events | 4 | 2 | 5 | 4 | 4 | 7 | 12 | 3 | 3 |
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. The number of participants with at least one TE AE was reported for each arm.
| Participants | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 9 | 3 | 6 | 8 | 5 | 11 | 23 | 10 | 12 |
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related. This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study. The number of participants that discontinued study treatment with bomedemstat due to a TE AE was reported for each arm.
| Participants | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants That Discontinued Study Treatment Due To AEs | 0 | 1 | 5 | 1 | 2 | 4 | 5 | 2 | 3 |
Cmax was defined as the maximum observed concentration after administration obtained directly from the concentration time profile. Blood and plasma samples were collected at pre-specified timepoints to calculate Cmax in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
| ng/mL | Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|
| Plasma | 12.63 ± 104.41 | — | — | — | — | — | — |
| Blood | 26.27 ± 66.76 | — | — | — | — | — | — |
Tmax was defined as the time to maximum concentration after administration obtained by inspection. Blood and plasma samples were collected at pre-specified timepoints to calculate Tmax in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
| hour | Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|
| Plasma | 1.00 (0.50 to 2.85) | — | — | — | — | — | — |
| Blood | 1.05 (0.50 to 3.02) | — | — | — | — | — | — |
AUC0-24 was defined as the area under the concentration versus time curve calculated using the linear trapezoidal rule from the zero time-point to the 24-hour time-point concentration. Blood and plasma samples were collected at pre-specified timepoints to calculate AUC0-24 in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
| hour•ng/mL | Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|
| Plasma | 63.90 ± 68.56 | — | — | — | — | — | — |
| Blood | 265.92 ± 68.92 | — | — | — | — | — | — |
CL/F was defined as the apparent total clearance of drug after oral administration. Blood and plasma samples were collected at pre-specified timepoints to calculate CL/F in participants of the Phase 1/2a portion of the study. As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
| mL/min | Ph 1/2a Portion: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|
| Plasma | 12787.43 ± 63.72 | — | — | — | — | — | — |
| Blood | 3067.57 ± 85.78 | — | — | — | — | — | — |
Change in spleen volume was assessed based on calculated spleen volume (ml) measured by magnetic resonance imaging (MRI), or computerized tomography (CT) scan (where locally permitted) if the participant was not a candidate for MRI from Day 0. Percentage change from baseline in spleen volume was reported at Initial Treatment Period (ITP) Day 84, ITP Day 168, Additional Treatment Period 1 (ATP1) Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337).
| Percentage Change | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| ITP Day 84 (Study Day 84) | 3.3 (-50.5 to 57.0) | -13.7 (-49.6 to 22.2) | 2.2 (-110.3 to 114.8) | -9.1 (-27.9 to 9.6) | -7.2 (-80.2 to 65.8) | 0.3 (-32.3 to 32.9) | 10.0 (1.2 to 18.8) | -2.3 (-31.5 to 26.9) | 1.2 (-10.9 to 13.2) |
| ITP Day 168 (Study Day 168) | — | — | — | -23.9 (-43.2 to -4.6) | -19.6 (NA to NA) | -33.7 (-43.8 to -23.6) | 12.3 (-4.1 to 28.6) | -15.4 (-56.7 to 25.8) | -4.4 (-20.6 to 11.8) |
| ATP1 Day 84 (Study Day 253) | — | — | — | — | — | -27.7 (NA to NA) | — | — | — |
| ATP1 Day 168 (Study Day 337) | — | — | — | -36.5 (NA to NA) | — | -38.9 (NA to NA) | 37.4 (-55.6 to 130.5) | 6.0 (-302.0 to 313.9) | -15.0 (-39.0 to 9.0) |
Change in spleen size was assessed based on spleen palpation (in cm) at each visit. Percentage change from baseline in spleen size was reported at ITP Day 84, ITP Day 168, ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591). As prespecified by the Statistical Analysis Plan, assessments for the Phase 1/2 groups were summarized using visit windowing after the Day 84 visit of the ITP to allow for comparison with the Phase 2b groups at ITP Day 168.
| Percentage Change | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| ITP Day 84 (Study Day 84) | -36.5 (-68.0 to -5.0) | 9.6 (-95.1 to 114.2) | 24.1 (-79.4 to 127.7) | 20.7 (-132.2 to 173.7) | -28.1 (-257.8 to 201.6) | 11.0 (-70.7 to 92.7) | -34.7 (-58.1 to -11.3) | -38.2 (-53.4 to -23.1) | -59.6 (-113.4 to -5.7) |
| ITP Day 168 (Study Day 168) | -20.7 (-48.3 to 6.9) | -39.6 (NA to NA) | 116.3 (-1794.8 to 2027.4) | -27.8 (NA to NA) | — | -36.1 (-212.6 to 140.4) | -24.8 (-74.2 to 24.5) | -28.5 (-60.1 to 3.0) | -41.2 (-102.9 to 20.6) |
| ATP1 Day 84 (Study Day 253) | — | — | — | -27.8 (NA to NA) | — | -36.1 (-212.6 to 140.4) | -27.9 (-84.8 to 29.0) | -50.4 (-101.7 to 0.9) | -28.4 (-97.7 to 40.9) |
| ATP1 Day 168 (Study Day 337) | -19.0 (NA to NA) | — | — | -27.8 (NA to NA) | — | -38.9 (-180.1 to 102.3) | -1.9 (-151.0 to 147.3) | -38.9 (NA to NA) | -82.4 (-117.4 to -47.4) |
| ATP2 Day 84 (Study Day 422) | -4.8 (NA to NA) | — | — | — | — | -37.5 (-196.3 to 121.3) | — | -44.4 (NA to NA) | — |
| ATP2 Day 168 (Study Day 506) | — | — | — | — | — | -22.0 (NA to NA) | — | — | — |
| ATP3 Day 84 (Study Day 591) | — | — | — | — | — | -11.1 (-152.3 to 130.1) | — | — | — |
Collected over Up to approximately 30 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | 0/9 (0%) | 4/9 (44.4%) | 9/9 (100%) |
| Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | 0/6 (0%) | 5/6 (83.3%) | 6/6 (100%) |
| Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | 1/8 (12.5%) | 4/8 (50%) | 8/8 (100%) |
| Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | 1/5 (20%) | 4/5 (80%) | 5/5 (100%) |
| Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | 0/11 (0%) | 7/11 (63.6%) | 11/11 (100%) |
| Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | 1/24 (4.2%) | 12/24 (50%) | 23/24 (95.8%) |
| Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | 0/11 (0%) | 3/11 (27.3%) | 10/11 (90.9%) |
| Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d | 0/13 (0%) | 3/13 (23.1%) | 12/13 (92.3%) |
| Event | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/9 | 2/3 | 2/6 | 0/8 | 1/5 | 2/11 | 1/24 | 1/11 | 1/13 |
| NauseaGastrointestinal disorders | 0/9 | 2/3 | 3/6 | 2/8 | 1/5 | 2/11 | 4/24 | 1/11 | 1/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/9 | 1/3 | 3/6 | 4/8 | 2/5 | 7/11 | 1/24 | 3/11 | 3/13 |
| AnaemiaBlood and lymphatic system disorders | 2/9 | 0/3 | 3/6 | 2/8 | 2/5 | 5/11 | 2/24 | 2/11 | 2/13 |
| GoutMetabolism and nutrition disorders | 0/9 | 0/3 | 3/6 | 0/8 | 0/5 | 1/11 | 1/24 | 0/11 | 0/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/9 | 1/3 | 3/6 | 0/8 | 2/5 | 2/11 | 3/24 | 1/11 | 0/13 |
| Oedema peripheralGeneral disorders | 2/9 | 0/3 | 1/6 | 4/8 | 2/5 | 1/11 | 1/24 | 1/11 | 1/13 |
| HeadacheNervous system disorders | 1/9 | 0/3 | 1/6 | 1/8 | 2/5 | 0/11 | 1/24 | 0/11 | 0/13 |
| PneumoniaInfections and infestations | 0/9 | 0/3 | 0/6 | 3/8 | 0/5 | 2/11 | 1/24 | 0/11 | 1/13 |
| Abdominal discomfortGastrointestinal disorders | 0/9 | 1/3 | 1/6 | 0/8 | 0/5 | 1/11 | 2/24 | 0/11 | 0/13 |
| Event | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d |
|---|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 5/9 | 2/3 | 4/6 | 7/8 | 3/5 | 8/11 | 4/24 | 6/11 | 4/13 |
| AnaemiaBlood and lymphatic system disorders | 7/9 | 2/3 | 5/6 | 2/8 | 3/5 | 5/11 | 5/24 | 3/11 | 3/13 |
| DiarrhoeaGastrointestinal disorders | 4/9 | 1/3 | 5/6 | 3/8 | 0/5 | 4/11 | 9/24 | 2/11 | 2/13 |
| NauseaGastrointestinal disorders | 0/9 | 2/3 | 3/6 | 5/8 | 2/5 | 3/11 | 7/24 | 3/11 | 2/13 |
| Upper respiratory tract infectionInfections and infestations | 1/9 | 2/3 | 1/6 | 1/8 | 0/5 | 0/11 | 0/24 | 0/11 | 0/13 |
| Weight decreasedInvestigations | 1/9 | 2/3 | 1/6 | 1/8 | 2/5 | 1/11 | 1/24 | 0/11 | 2/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/9 | 2/3 | 3/6 | 0/8 | 2/5 | 2/11 | 5/24 | 3/11 | 1/13 |
| DizzinessNervous system disorders | 1/9 | 2/3 | 1/6 | 0/8 | 1/5 | 1/11 | 1/24 | 2/11 | 0/13 |
| DysgeusiaNervous system disorders | 6/9 | 2/3 | 3/6 | 3/8 | 0/5 | 4/11 | 6/24 | 3/11 | 5/13 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/9 | 2/3 | 2/6 | 2/8 | 0/5 | 1/11 | 2/24 | 1/11 | 2/13 |
| Age, Continuous(Years) | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.6 ± 12.43 | 74.7 ± 5.51 | 64.7 ± 6.59 | 69.6 ± 8.38 | 64.8 ± 7.46 | 69.4 ± 14.40 | 65.2 ± 9.42 | 66.7 ± 9.27 | 61.3 ± 12.07 | 65.7 ± 10.51 |
| Sex: Female, Male(Participants) | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 4 | 4 | 4 | 6 | 12 | 8 | 4 | 43 |
| Male | 8 | 3 | 2 | 4 | 1 | 5 | 12 | 3 | 9 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 3 |
| Not Hispanic or Latino | 8 | 3 | 5 | 8 | 4 | 10 | 22 | 11 | 9 | 80 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 4 | 7 |
| Race/Ethnicity, Customized(Participants) | Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d | Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d | Ph 2b PMF: Bomedemstat 0.5 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d | Ph 2b PMF: Bomedemstat 0.6 mg/kg/d | Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d | Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 10 | 5 | 5 | 21 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| White | 7 | 2 | 6 | 7 | 4 | 9 | 12 | 6 | 6 | 59 |
| Other | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Multiple | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not Reported | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2017 to primary completion in Mar 2022, 55 months.
Results were first posted in Jan 2024, 1 year 10 months after primary completion. A results delay was requested in Feb 2023.
Of 26 phase 1/2 interventional studies under Primary Myelofibrosis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 125. This study's 55 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) →